Buys | $74,000 | 2 | 5 |
Sells | $56,911,478 | 39 | 95 |
Rothenberg Mace | director | 2 | $74,000 | 0 | $0 | $74,000 |
Barry Douglas | General Counsel | 0 | $0 | 2 | $16,369 | $-16,369 |
Beckman Daniella | Chief Financial Officer | 0 | $0 | 2 | $25,282 | $-25,282 |
Calhoun Lesley Ann | director | 0 | $0 | 1 | $36,039 | $-36,039 |
Crystal Adam | See Remarks | 0 | $0 | 2 | $43,866 | $-43,866 |
Weber Barbara | Chief Executive Officer | 0 | $0 | 2 | $57,710 | $-57,710 |
MVA Investors, LLC | See remarks | 0 | $0 | 8 | $4.62M | $-4.62M |
EcoR1 Capital, LLC | 10 percent owner | 0 | $0 | 2 | $8.44M | $-8.44M |
Boxer Capital Management, LLC | See remarks | 0 | $0 | 4 | $20.12M | $-20.12M |
Third Rock Ventures IV, L.P. | 10 percent owner | 0 | $0 | 16 | $23.55M | $-23.55M |
Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with …
Over the last 12 months, insiders at Tango Therapeutics, Inc. have bought $74,000 and sold $56.91M worth of Tango Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Tango Therapeutics, Inc. have bought $4.58M and sold $20.49M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rothenberg Mace (director) — $74,000.
The last purchase of 10,000 shares for transaction amount of $37,800 was made by Rothenberg Mace (director) on 2024‑11‑18.
2025-02-05 | Sale | Weber Barbara | Chief Executive Officer | 9,013 0.0087% | $3.16 | $28,494 | -31.34% | |
2025-02-05 | Sale | Crystal Adam | See Remarks | 6,851 0.0066% | $3.16 | $21,659 | -31.34% | |
2025-02-05 | Sale | Beckman Daniella | Chief Financial Officer | 3,948 0.0038% | $3.16 | $12,481 | -31.34% | |
2025-02-05 | Sale | Barry Douglas | General Counsel | 2,556 0.0025% | $3.16 | $8,081 | -31.34% | |
2025-02-04 | Sale | Weber Barbara | Chief Executive Officer | 9,778 0.0093% | $2.99 | $29,217 | -23.52% | |
2025-02-04 | Sale | Crystal Adam | See Remarks | 7,432 0.0071% | $2.99 | $22,207 | -23.52% | |
2025-02-04 | Sale | Beckman Daniella | Chief Financial Officer | 4,284 0.0041% | $2.99 | $12,801 | -23.52% | |
2025-02-04 | Sale | Barry Douglas | General Counsel | 2,774 0.0027% | $2.99 | $8,289 | -23.52% | |
2024-11-18 | Rothenberg Mace | director | 10,000 0.0098% | $3.78 | $37,800 | -15.56% | ||
2024-11-14 | Rothenberg Mace | director | 10,000 0.0088% | $3.62 | $36,200 | -22.45% | ||
2024-11-07 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.21M 1.1237% | $2.94 | $3.54M | +7.60% | |
2024-11-06 | Sale | EcoR1 Capital, LLC | 10 percent owner | 1.49M 1.3103% | $3.28 | $4.9M | -6.17% | |
2024-11-06 | Sale | Boxer Capital Management, LLC | See remarks | 3.08M 2.5882% | $3.14 | $9.67M | -6.17% | |
2024-10-25 | Sale | Boxer Capital Management, LLC | See remarks. | 633,000 0.6113% | $6.87 | $4.35M | -48.40% | |
2024-10-22 | Sale | Boxer Capital Management, LLC | See remarks | 250,000 0.2383% | $6.78 | $1.7M | -53.61% | |
2024-10-21 | Sale | Boxer Capital Management, LLC | See remarks | 625,000 0.5752% | $7.05 | $4.41M | -56.92% | |
2024-09-13 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 67,400 0.0631% | $10.53 | $709,756 | -69.24% | |
2024-09-05 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 75,000 0.0693% | $11.56 | $867,135 | -72.09% | |
2024-08-30 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 175,000 0.1601% | $11.60 | $2.03M | -71.85% | |
2024-08-27 | Sale | Third Rock Ventures IV, L.P. | 10 percent owner | 25,000 0.0236% | $11.55 | $288,665 | -70.61% |
Rothenberg Mace | director | 31250 0.0289% | $60,937.50 | 2 | 0 | |
Boxer Capital, LLC | 8198642 7.5838% | $15.99M | 3 | 1 | +19.37% | |
Davis Aaron I. | director | 7123642 6.5894% | $13.89M | 3 | 0 | +36.79% |
LEWIS JOSEPH | director | 7053642 6.5246% | $13.75M | 3 | 0 | +40.76% |
BCTG Holdings, LLC | 10 percent owner | 4488450 4.1518% | $8.75M | 1 | 1 | +7.42% |
$21,574,635 | 88 | 2.81% | $211.87M | |
$7,150,333 | 87 | -8.28% | $221.99M | |
$613,304,943 | 46 | 11.85% | $181.55M | |
$48,218,096 | 42 | 0.89% | $210.73M | |
$2,545,071 | 34 | 16.59% | $241.88M |
Increased Positions | 86 | +64.66% | 41M | +40.23% |
Decreased Positions | 53 | -39.85% | 27M | -26.97% |
New Positions | 44 | New | 39M | New |
Sold Out Positions | 27 | Sold Out | 11M | Sold Out |
Total Postitions | 166 | +24.81% | 115M | +13.26% |
Trv Gp Iv, Llc | $32,875.00 | 15.61% | 16.86M | 0 | 0% | 2024-12-31 |
Tcg Crossover Management, Llc | $20,935.00 | 9.94% | 10.74M | +11M | New | 2024-12-31 |
Ecor1 Capital, Llc | $20,730.00 | 9.84% | 10.63M | -3M | -20.25% | 2024-12-31 |
Boxer Capital Management, Llc | $20,243.00 | 9.61% | 10.38M | +10M | New | 2024-12-31 |
Boxer Capital, Llc | $15,987.00 | 7.59% | 8.2M | 0 | 0% | 2024-09-30 |
Nextech Invest Ltd. | $10,791.00 | 5.12% | 5.53M | 0 | 0% | 2024-12-31 |
Gilead Sciences, Inc. | $9,466.00 | 4.5% | 4.85M | +5M | New | 2024-12-31 |
Blackrock, Inc. | $8,538.00 | 4.05% | 4.38M | +17,168 | +0.39% | 2024-12-31 |
Farallon Capital Management Llc | $7,800.00 | 3.7% | 4M | +4M | New | 2024-12-31 |
Vanguard Group Inc | $7,771.00 | 3.69% | 3.99M | +339,922 | +9.32% | 2024-12-31 |